4/A//SEC Filing
Q Therapeutics, Inc. 4/A
Accession 0001209191-16-098143
CIK 0001366541operating
Filed
Feb 11, 7:00 PM ET
Accepted
Feb 12, 5:02 PM ET
Size
10.3 KB
Accession
0001209191-16-098143
Insider Transaction Report
Form 4/AAmended
Q Therapeutics, Inc.[NONE]
BORST STEVEN JOHN
CFO & VP of Corp. Development
Transactions
- Award
Option to Purchase Common Stock
2015-09-09$0.70/sh+400,000$280,000→ 2,750,274 totalExercise: $0.70From: 2016-09-08Exp: 2025-09-08→ Common Stock (400,000 underlying) - Award
Option to Purchase Common Stock
2015-09-09$0.70/sh+100,000$70,000→ 2,850,274 totalExercise: $0.70Exp: 2025-09-08→ Common Stock (100,000 underlying) - Award
Option to Purchase Common Stock
2015-09-09$0.70/sh+100,000$70,000→ 2,950,274 totalExercise: $0.70Exp: 2025-09-08→ Common Stock (100,000 underlying)
Footnotes (3)
- [F1]Option shall vest at the rate of 28% on the one year anniversary of the grant date and 2% per month thereafter.
- [F2]Option will vest in full upon the closing of an equity and/or debt financing in the cumulative amount of $10 million on or prior to June 30, 2016.
- [F3]Option to vest in full upon the first patient dosed in the Company's Phase I clinical trial.
Documents
Issuer
Q Therapeutics, Inc.
CIK 0001366541
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001366541
Filing Metadata
- Form type
- 4/A
- Filed
- Feb 11, 7:00 PM ET
- Accepted
- Feb 12, 5:02 PM ET
- Size
- 10.3 KB